Calmark Sweden AB

FRA:9C7 (Sweden)   Ordinary Shares - Class B
€ 0.00 (0%) Mar 19
At Loss
P/B:
0.18
Market Cap:
€ 23.00K ($ 25.00K)
Enterprise V:
€ -1.33M ($ -1.42M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Calmark Sweden AB ( FRA:9C7 ) from 2021 to May 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Calmark Sweden AB stock (FRA:9C7) PE ratio as of May 01 2024 is 0. More Details

Calmark Sweden AB (FRA:9C7) PE Ratio (TTM) Chart

To

Calmark Sweden AB (FRA:9C7) PE Ratio (TTM) Historical Data

Total 744
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 9
Calmark Sweden AB PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-02 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-12 At Loss
2024-03-15 At Loss 2024-01-11 At Loss
2024-03-14 At Loss 2024-01-10 At Loss
2024-03-13 At Loss 2024-01-09 At Loss
2024-03-12 At Loss 2024-01-08 At Loss
2024-03-11 At Loss 2024-01-05 At Loss
2024-03-08 At Loss 2024-01-04 At Loss
2024-03-07 At Loss 2024-01-03 At Loss
2024-03-06 At Loss 2024-01-02 At Loss
2024-03-05 At Loss 2023-12-29 At Loss
2024-03-04 At Loss 2023-12-28 At Loss
2024-03-01 At Loss 2023-12-27 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-19 At Loss 2023-12-12 At Loss
2024-02-16 At Loss 2023-12-11 At Loss
2024-02-15 At Loss 2023-12-08 At Loss
2024-02-14 At Loss 2023-12-07 At Loss
2024-02-13 At Loss 2023-12-06 At Loss
2024-02-12 At Loss 2023-12-05 At Loss
2024-02-09 At Loss 2023-12-04 At Loss
2024-02-08 At Loss 2023-12-01 At Loss
2024-02-07 At Loss 2023-11-30 At Loss
2024-02-06 At Loss 2023-11-29 At Loss
2024-02-05 At Loss 2023-11-28 At Loss
2024-02-02 At Loss 2023-11-27 At Loss
2024-02-01 At Loss 2023-11-24 At Loss
2024-01-31 At Loss 2023-11-23 At Loss
2024-01-30 At Loss 2023-11-22 At Loss
2024-01-29 At Loss 2023-11-21 At Loss
2024-01-26 At Loss 2023-11-20 At Loss
2024-01-25 At Loss 2023-11-17 At Loss
2024-01-24 At Loss 2023-11-16 At Loss
2024-01-23 At Loss 2023-11-15 At Loss
2024-01-22 At Loss 2023-11-14 At Loss
2024-01-19 At Loss 2023-11-10 At Loss
2024-01-18 At Loss 2023-11-09 At Loss

Calmark Sweden AB (FRA:9C7) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Calmark Sweden AB provides tests for a newborn. The company's product Calmark's developed a point-of-care (POC) diagnostic instrument which makes it easier and faster to measure biomarkers for disease states in newborns. The company's PNA instrument consists of a reader and a disposable product that is placed in the reader when measured.